Thermo Fisher Scientific Inc. and QIAGEN N.V. announced that they have entered into an amendment to their acquisition agreement under which Thermo Fisher has commenced a tender offer to acquire all of the ordinary shares of QIAGEN.
The amendment provides for an increase from the original offer price of €39.00 to a new price of €43.00 per QIAGEN share in cash, which represents a premium of approximately 35% to the closing price of QIAGEN’s ordinary shares on the Frankfurt Prime Standard on March 2, 2020, the last trading day prior to the announcement of the acquisition agreement and Thermo Fisher’s intention to commence the offer. The amendment also provides for a reduction of the minimum acceptance threshold from 75% to 66.67% of QIAGEN’s issued and outstanding ordinary share capital at the end of the acceptance period on August 10, 2020, as well as a USD 95 million expense reimbursement to Thermo Fisher if the minimum acceptance threshold is not met.
The members of QIAGEN’s Supervisory Board and Managing Board have reaffirmed their unanimous support for the offer and their unanimous recommendation that all QIAGEN shareholders accept and tender all of their QIAGEN shares in the offer prior to the end of the acceptance period, which has now been extended to August 10, 2020. Each of the members of the Supervisory Board and Managing Board has tendered or will tender all of their QIAGEN shares in the offer.
Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific, said, “Industry dynamics have changed considerably in the past few months, creating tailwinds and headwinds for our businesses. Both of our companies are playing important roles in helping customers to battle the COVID-19 pandemic. After careful consideration, we’ve decided to increase our offer for QIAGEN to reflect the fair value of the business given the current environment. We remain confident that this transaction will create shareholder value and, importantly, provide meaningful benefits to our customers and society by combining our capabilities to combat infectious diseases and other healthcare issues. We continue to look forward to completing the transaction in the first half of 2021.”
“After carefully considering the updated offer by Thermo Fisher, QIAGEN’s Supervisory Board and Managing Board both unanimously recommend that shareholders accept this offer given that it reflects the improvements in our business performance and future prospects as a result of the coronavirus pandemic,” said Thierry Bernard, chief executive officer of QIAGEN N.V. “The rationale for this strategic step is stronger than ever, especially as the value of molecular testing becomes ever more evident. This combination is designed to enable QIAGEN employees and our portfolio of Sample to Insight solutions to have an even greater impact on society while also delivering significant cash value to our shareholders. We look forward to working closely with Thermo Fisher to successfully complete the transaction.”
QIAGEN shareholders who have already effectively accepted the offer by tendering their shares are not required to take further action in order to receive the increased offer price in accordance with the terms of the offer. Thermo Fisher’s tender offer statement on Schedule TO, including the offer document that is an exhibit thereto, and QIAGEN’s solicitation/recommendation statement on Schedule 14D-9 will be amended to reflect the revised terms of the transaction. The acceptance period is now scheduled to expire at 24:00 hours (Frankfurt am Main local time) / 18:00 hours (New York local time) on August 10, 2020.
QIAGEN acquires majority stake in enzymes provider BLIRT S.A.
QIAGEN N.V. announced that it has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A., a manufacturer of recombinant enzymes for the life science industry based in Gdansk, Poland. BLIRT develops, manufactures and commercializes standardized and customized solutions for ... more
Life-science start-up Actome and QIAGEN announce commercial partnership
Actome GmbH, a life-science start-up company from the University of Freiburg and Hahn-Schickard, Germany has signed a license agreement and a co-marketing agreement with QIAGEN GmbH, Hilden, Germany, to jointly accelerate the market entry of Actome’s Protein-Interaction-Coupling (PICO) Tech ... more
QIAGEN expands Supervisory Board with appointment of a new member
QIAGEN announced the appointment of Thomas Ebeling, a leading international executive with extensive experience in the healthcare, media and consumer goods industries, as a member of the Supervisory Board with immediate effect. Mr. Ebeling joins QIAGEN as part of a process launched by the S ... more
HAMILTON Robotics designs and manufactures fully automated robotic systems. The products range from unique, custom laboratory automation solutions (Turnkey Solutions) on standard applications validated through partnership programs with renowned biotechnology companies as well as OEM solutio ... more
BMG LABTECH offers high-end plate reader solutions for drug discovery and HTS. The plate readers provides best sensitivity, best flexibility and reliability. The integration of these microplate readers into robotic systems is easy; especially for the robot integration in high throughput scr ... more
CANDOR Bioscience GmbH is an internationally oriented enterprise which develops, produces and distributes a comprehensive selection of premium solutions for immunoassays. CANDOR offers more than 50 different products including HAMA and interference blockers, surface blockers, stabilizers a ... more
Thermo Fisher Scientific announces collaboration with Celltrio
Thermo Fisher Scientific and Celltrio, a manufacturer of robotics-based solutions for the life sciences industry, have announced their collaboration to bring a fully automated cell culture system to biotherapeutics customers. The collaboration will integrate the Thermo Scientific Momentum w ... more
Thermo Fisher Scientific to Acquire The Binding Site Group
Thermo Fisher Scientific Inc. announced that it has entered into a definitive agreement to acquire The Binding Site Group, a global leader in specialty diagnostics, from a shareholder group led by European private equity firm Nordic Capital, in an all-cash transaction valued at £2.25 billio ... more
LabCentral, the first-of-its-kind shared laboratory space designed as a launchpad for high-potential biotech startups, announced a total of $22.4 million in sponsorship commitments for LabCentral 238, a fully functional life sciences laboratory with a focus on scale-up bio-manufacturing. Th ... more
Thermo Scientific™ Charged Aerosol Detectors: See what you've been missing - Hidden peaks revealed
Sensitive, universal detection with a near-uniform response ✓ Measures any non-volatile and semi-volatile analytes at sub-nanogram ✓ Does not require a chromophore or ionization more
Vanquish Neo UHPLC for LC-MS applications in proteomics, precision medicine, translational research
All-in-one nano-, capillary- and micro-flow LC for high sensitivity LC-MS workflows ✓ Accelerating productivity with long-term trouble-free operation at maximum performance ✓ Intelligent at-system or remote control, method setup, diagnostics and troubleshooting ✓ more
New Thermo Scientific Orbitrap Exploris Mass Spectrometry Systems
Market leading resolution for uncompromising data certainty ✓ Day-to-day performance consistency ✓ Out-of-the-box simplicity with a compact footprint more
Thermo Scientific™ Charged Aerosol Detectors: See what you've been missing - Hidden peaks revealed
The problem with almost every other type of detector is that there is a bias. The bias might be that one analyte responds more than another or that mobile phase affects detection differently. A charged aerosol detector measures analyte charge that is in direct proportion to the amount of th ... more
Be a Pioneer – the Freedom to Explore Ion Chromatography
When addressing ion analysis challenges, there are sometimes more questions than answers. The ability to develop and run different methods for a single sample or for different samples is increasingly important for analytical laboratories. The Thermo Scientific™ Dionex™ ICS-6000 HPIC™ System ... more
Most Advanced HPLC Systems with Excellent Retention Time Stability and Precision
Designed with innovative technology and attention to fine detail, Thermo Scientific™Vanquish™ HPLC and UHPLC systems are the most advanced LC instruments available: Vanquish Core HPLC system delivers absolute dependability to enable worry-free applications. Vanquish Flex UHPLC systems offer ... more
Learn how breath analysis can detect disease and cancer in its early stage
Breath Biopsy offers a non-invasive and pain free way to monitor human biology and enable the critical early detection of disease more
Clinical research and forensic handbook
Comprehensive collection of information for clinical/translational/drug monitoring research, forensic testing, and sports antidoping analysis more
Delivering on the Promise of the Paperless Lab
Organizations have made significant investments in enterprise and laboratory tools, technologies and solutions to help improve productivity, better manage data/information and optimize their business processes. However, the reality is that most comp more
Thermo Fisher Scientific is the world leader in serving science. We enabling our customers to make the world healthier, cleaner and safer. With our brand Thermo Scientific we offer solutions for Chromatography, Elemental Analysis, Mass Spectrometry, Molecular Spectroscopy as well as Labor ... more
Thermo Fisher Scientific BRAHMS GmbH
B·R·A·H·M·S explores, develops and produces new diagnostic test procedures to improve the diagnosis, and thereby the treatment, of life-threatening illnesses. This takes place with over 300 employees, on the basis of our own patented biomarkers, and leads to medically and economically supe ... more
Thermo Fisher Scientific is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research ... more
